drugset / Trial / NCT05179356
Dapagliflozin in Pulmonary Arterial Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension
Timeline
- Start
- 2023-01-01
- Primary completion
- 2026-01-13
- Completion
- 2026-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |